Lucke Andrea, Kiermaier Josef, Göpferich Achim
Department of Pharmaceutical Technology, University of Regensburg, Germany.
Pharm Res. 2002 Feb;19(2):175-81. doi: 10.1023/a:1014272816454.
Poly(lactic acid) (PLA) and poly(lactic-co-glycolic acid) (PLGA) microspheres were investigated concerning the possible acylation of incorporated peptides.
Atrial natriuretic peptide (ANP) and salmon calcitonin (sCT) were encapsulated into PLA and PLGA microspheres. Peptide integrity was monitored by HPLC-MS analysis during microsphere degradation for four weeks. sCT fragmentation with endoproteinase Glu-C was used for identifying modified amino acids. Peptide stability in lactic acid solutions was investigated to elucidate possible mechanisms for preventing peptide acylation.
Both peptides were acylated by lactic and glycolic acid units inside degrading microspheres in a time-dependent manner. After 21 days, 60% ANP and 7% sCT inside PLA microspheres were acylated. Fragmentation of sCT with endoproteinase Glu-C revealed that besides the N-terminal amine group, lysine, tyrosine or serine are further possible targets to acylation. Stability studies of the peptides in lactic acid solutions suggest that oligomers are the major acylation source and that lower oligomer concentration and higher pH substantially decreased the reaction velocity.
The use of PLA and PLGA for drug delivery needs substantially more circumspection. As, according to FDA standards. the potential hazards of peptide acylation products need to be assessed, our findings may have significant implications for products already on the market. Techniques to minimize the acylation reaction are suggested.
研究聚乳酸(PLA)和聚乳酸 - 乙醇酸共聚物(PLGA)微球中所含肽可能发生的酰化作用。
将心钠素(ANP)和鲑鱼降钙素(sCT)包封于PLA和PLGA微球中。在微球降解4周的过程中,通过高效液相色谱 - 质谱分析监测肽的完整性。用内肽酶Glu - C对sCT进行片段化分析以鉴定修饰的氨基酸。研究肽在乳酸溶液中的稳定性,以阐明防止肽酰化的可能机制。
在降解的微球中,两种肽均被乳酸和乙醇酸单元以时间依赖性方式酰化。21天后,PLA微球内60%的ANP和7%的sCT被酰化。用内肽酶Glu - C对sCT进行片段化分析表明,除了N端胺基外,赖氨酸、酪氨酸或丝氨酸也是酰化的其他可能靶点。肽在乳酸溶液中的稳定性研究表明,低聚物是主要的酰化来源,较低的低聚物浓度和较高的pH值可显著降低反应速度。
使用PLA和PLGA进行药物递送需要更加谨慎。由于根据美国食品药品监督管理局(FDA)标准,需要评估肽酰化产物的潜在危害,我们的研究结果可能对已上市产品具有重大意义。文中提出了使酰化反应最小化的技术。